EC Number | Application | Comment | Organism |
---|---|---|---|
1.14.19.17 | pharmacology | the cells capacity to biosynthesize dihydroceramides must be taken into account in proautophagic Des1 inhibitors-including therapies | Homo sapiens |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
1.14.19.17 | celecoxib | CCX | Homo sapiens | |
1.14.19.17 | fenretinide | - |
Homo sapiens | |
1.14.19.17 | additional information | in T98G and U87MG glioblastoma cell lines different Des1 inhibitory pro-autophagic compounds (DIPACS) exhibiting different cytotoxicities (CCX, PXD, resveratrol, gamma-tocotrienol and XM462), trigger autophagy via different pathways, both dihydroceramide-dependent and independent pathways | Homo sapiens | |
1.14.19.17 | phenoxodiol | PXD | Homo sapiens | |
1.14.19.17 | resveratrol | - |
Homo sapiens | |
1.14.19.17 | tetrahydrocannabinol | - |
Homo sapiens | |
1.14.19.17 | XM462 | an active-site directed Des1 inhibitor | Homo sapiens |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.14.19.17 | tetracosanoyl-dihydroceramide + reduced acceptor + O2 + 2 H+ | Homo sapiens | - |
? | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
1.14.19.17 | Homo sapiens | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
1.14.19.17 | glioblastoma cell | - |
Homo sapiens | - |
1.14.19.17 | T-98G cell | - |
Homo sapiens | - |
1.14.19.17 | U-87DND cell | - |
Homo sapiens | - |
1.14.19.17 | U-87MG cell | - |
Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.14.19.17 | N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-erythro-sphinganine + reduced acceptor + O2 + 2 H+ | - |
Homo sapiens | ? | - |
? | |
1.14.19.17 | tetracosanoyl-dihydroceramide + reduced acceptor + O2 + 2 H+ | - |
Homo sapiens | ? | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
1.14.19.17 | dihydroceramide desaturase | - |
Homo sapiens |
EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|---|
1.14.19.17 | 37 | - |
in vivo assay at | Homo sapiens |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
1.14.19.17 | cytochrome b5 | - |
Homo sapiens |
EC Number | Organism | Comment | Expression |
---|---|---|---|
1.14.19.17 | Homo sapiens | gamma-tocotrienol causes downregulation of Des1 expression but is not inhibitory for the enzyme activity | down |
EC Number | General Information | Comment | Organism |
---|---|---|---|
1.14.19.17 | malfunction | dihydroceramide desaturase 1 inhibitors activate autophagy via both dihydroceramide-dependent and independent pathways and the balance between the two pathways influences the final cell fate. Enzyme inhibitors celecoxib, resveratrol, phenoxodiol, and gamma-tocotrienol, but not gamma-tocopherol at 0.05 mM, promote an increase in dihydroceramide, dihydrosphingomyelins, and lactosyldihydroceramides in U-87MG and T-98G cell lines. Similar results are found with the active site-directed Des1 inhibitor XM462 | Homo sapiens |